TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Conclusion This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy. Micro-Abstract Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Aeyung Kim, Jin Yeul Ma
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday. The job shuffling has implications up and down the employment ranks of the Bay Area's two largest drug makers during critical times for both companies. Gilead (NASDAQ: GILD), based in Foster City, is set up for deeper moves into next-generation cancer drugs while South San Francisco's…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Two people developed cancer after organ donations from a woman who had the undetected disease.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
This study explores the prevalence of clonal hematopoiesis related to radioactive iodine exposure and how it impacts overall survival in patients with thyroid cancer.Journal of Clinical Endocrinology &Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Training programs are needed to help employers improve communication with cancer survivors and facilitate workplace accommodations.Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Objective: To investigate the clinical features of 2nd hematological malignancies post to the initial cancer treatment.METHODS: A retrospective study was performed to analyze the available clinical data of 116 patients diagnosed with 2nd hematologic malignancies after treatment of various malignant tumors from June 1998 to June 2018 at Sun Yat-sen University cancer center.RESULTS: The characteristics of the 116 patients diagnosed with 2nd hematological cancer post to initial cancer treatment were indicated as following: 62 males and 54 females. The primary tumor category was grouped as (according to ICD-10 International Di...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
Abstract Essential facts Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. The main categories are lymphoma, leukaemia, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms. In addition, there are subtypes of lymphoma and leukaemia, as well as more rare haematological cancers that have their own categories. There are also borderline conditions such as aplastic anaemia and other non-malignant bone marrow failure syndromes. The charity Bloodwise says 38,000 people in Britain are diagnosed every year with blood cancer or a related disor...
Source: Nursing Standard - Category: Nursing Authors: Tags: Nurs Stand Source Type: research
Conclusion In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in twelve patients (18%). HCS identification provides insight for improved and individualized treatment, and screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis, and advocates that with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germline testing. Teaser The clinical importance and anticipated results of geneti...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in 12 patients (18%). HCS identification provides insight for improved and individualized treatment, as well as screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis; with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germ-line testing. PMID: 27210295 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Conclusion Lenalidomide appears to yield a higher HI-E rate in non-del5q LR-MDS when used as first-line therapy after ESA treatments failure. If validated in larger cohorts, lenalidomide rather than azacitidine should be considered for first-line therapy after ESA treatment failure. Micro-Abstract In patients with lower-risk myelodysplastic syndromes (LR-MDS) in whom treatment with erythropoiesis-stimulating agents (ESAs) fail, optimal sequencing of lenalidomide and azanucleosides is unknown. In a retrospective analysis of patients who received azacitidine and lenalidomide, the erythroid hematologic improvement rate was 3...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants